The New York Times has published an article about the use of ghost writers from drug companies to produce journal articles that then go out under the names of academics in US universities. This is yet another example of problems in the ethical standards of the big journal publishers and the morality in pockets of the global scholarly prestige system.
Senator moves to block medical ghostwriting
A growing body of evidence suggests that doctors at some of the nation’s top medical schools have been attaching their names and lending their reputations to scientific papers that were drafted by ghostwriters working for drug companies — articles that were carefully calibrated to help the manufacturers sell more products.
Experts in medical ethics condemn this practice as a breach of the public trust. Yet many universities have been slow to recognize the extent of the problem, to adopt new ethical rules or to hold faculty members to account.